To the editor, I am writing to highlight an important yet underexplored topic in women’s health: the potential relationship between hormonal contraceptives and urinary tract infections (UTIs). While UTIs are among the most common bacterial infections, affecting millions of women annually, the role of contraceptive methods in predisposing women to UTIs remains poorly understood. This issue warrants further investigation, as it could have significant implications for both clinical practice and public health. Hormonal contraceptives, including oral contraceptive pills, patches, and vaginal rings, are widely used by women worldwide. These methods primarily work by altering hormone levels to prevent pregnancy, but they may also influence other physiological systems, including the urinary tract. Estrogen, a key hormone in many contraceptives, plays a critical role in maintaining the health of the urogenital tract. It helps preserve the integrity of the vaginal and urethral epithelium, supports the growth of beneficial lactobacilli in the vaginal microbiome, and maintains a low pH environment that inhibits the growth of pathogenic bacteria. Disruptions in these mechanisms, whether due to hormonal fluctuations or contraceptive use, could potentially increase susceptibility to UTIs 1,2. Emerging evidence suggests that certain contraceptive methods may alter the urogenital microenvironment, creating conditions that favor bacterial colonization and infection. For example, some studies have indicated that the use of spermicides, particularly in combination with diaphragms, is associated with an increased risk of UTIs. This is thought to occur due to the disruption of the vaginal microbiome and the promotion of Escherichia coli colonization, the primary pathogen responsible for UTIs. Similarly, hormonal contraceptives that reduce estrogen levels may lead to atrophic changes in the urogenital tract, further increasing vulnerability to infections 3,4. Despite these observations, the relationship between hormonal contraceptives and UTIs remains complex and not fully elucidated. Some studies have found no significant association between oral contraceptive use and UTI risk, while others suggest that specific formulations or delivery methods may have varying effects. This inconsistency underscores the need for more robust, large-scale studies to clarify the potential link and identify which contraceptive methods, if any, may pose a higher risk for UTIs 5,6. I propose a comprehensive research approach to investigate this relationship further. Longitudinal studies could track UTI incidence among women using different contraceptive methods, controlling for confounding factors, such as sexual activity, hygiene practices, and underlying medical conditions. Additionally, laboratory studies could explore how hormonal contraceptives affect the urogenital microbiome, epithelial integrity, and immune responses to bacterial pathogens. Understanding these mechanisms could lead to the development of targeted interventions, such as probiotics or hormone-based therapies, to reduce UTI risk in contraceptive users 7,8. Furthermore, raising awareness among healthcare providers and patients about the potential connection between contraceptives and UTIs is crucial. Women should be informed about the possible risks and benefits of different contraceptive methods, enabling them to make informed decisions about their reproductive health. For those at higher risk of UTIs, alternative contraceptive options or preventive measures, such as increased hydration or postcoital antibiotics, could be considered. In conclusion, the potential relationship between hormonal contraceptives and UTIs represents a significant area of research that could improve women’s health outcomes. By deepening our understanding of this connection, we can develop evidence-based guidelines to minimize UTI risk while ensuring access to safe and effective contraceptive options. I encourage researchers and clinicians to prioritize this topic and collaborate on studies that shed light on this important issue. Financial support and sponsorship Nil. Conflicts of interest No conflict of interest.
Falah H.O. AL-Khikani (Wed,) studied this question.